
    
      Anti- CAR is a chimeric antigen receptor immunotherapy treatment designed to treat
      lymphoma/leukemia expressing CD5 antigen. CD5+ T cell lymphomas or leukemia are a subset of
      leukemias and lymphomas that are positive for the surface protein CD5. The purpose of this
      study is to evaluate the efficacy and safety of anti-CD5 CAR T cells.
    
  